Source
Amyloidosis News Today
Amvuttra (vutrisiran) rapidly and consistently reduces blood levels of transthyretin (TTR), the disease-causing protein in hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), across a wide range of patients, according to clinical trial data.
Similar sustained reductions were seen in people with transthyretin amyloid cardiomyopathy (ATTR-CM), a related disease marked mainly by heart damage instead of neurological damage.
The treatment’s effect was generally consistent across age, sex, body weight, genetic background, disease severity, and other initial patient characteristics.
News Url